The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as ...
GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
GlaxoSmithKline Pharmaceuticals shares jumped 16% after reporting a five-fold increase in net profit for the third quarter, ...
9h
GlobalData on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.
GSK said its five-in-one meningococcal vaccine Penmenvy was approved by the U.S. Food and Drug Administration. The British pharmaceutical company on Monday said the vaccine was authorized for use in ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals ...
15hon MSN
GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...
The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results